Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSITION20 trial of osimertinib in EGFR exon 20 non-T790M NSCLC
NL-OMON55798Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Primary endpoint: Best response. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55798.